References

[1] B. Goldstein and A. Goldstein. "Topical corticosteroids: Use and adverse effects." https://www.uptodate.com/contents/topical-corticosteroids-use-and-adverse-effects (accessed 11/6/22, 2022).

[2] M. Furue et al., "Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis," British Journal of Dermatology, https://doi.org/10.1046/j.1365-2133.2003.04934.x vol. 148, no. 1, pp. 128-133, 2003/01/01 2003, doi: https://doi.org/10.1046/j.1365-2133.2003.04934.x.

[3] B. S. Kim, M. D. Howell, K. Sun, K. Papp, A. Nasir, and M. E. Kuligowski, "Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream," (in eng), J Allergy Clin Immunol, vol. 145, no. 2, pp. 572-582, Feb 2020, doi: 10.1016/j.jaci.2019.08.042.

[4] E. J. Glazenburg, A. Wolkerstorfer, A. L. Gerretsen, P. G. Mulder, and A. P. Oranje, "Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls?," (in eng), Pediatr Allergy Immunol, vol. 20, no. 1, pp. 59-66, Feb 2009, doi: 10.1111/j.1399-3038.2008.00735.x.

[5] J. A. Broeders, U. Ahmed Ali, and G. Fischer, "Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience," (in eng), J Am Acad Dermatol, vol. 75, no. 2, pp. 410-419.e3, Aug 2016, doi: 10.1016/j.jaad.2016.02.1228.

[6] W. Howe. "Treatment of Atopic Dermatitis." https://www.uptodate.com/contents/treatment-of-atopic-dermatitis-eczema (accessed 11/6/22, 2022).

[7] W. Abramovits, A. B. Fleischer, Jr., E. Jaracz, and D. Breneman, "Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream," (in eng), J Drugs Dermatol, vol. 7, no. 12, pp. 1153-8, Dec 2008.

[8] L. Väkevä et al., "Narrowband ultraviolet B phototherapy improves quality of life of psoriasis and atopic dermatitis patients up to 3 months: Results from an observational multicenter study," (in eng), Photodermatol Photoimmunol Photomed, vol. 35, no. 5, pp. 332-338, Sep 2019, doi: 10.1111/phpp.12479.

[9] S. Feldman. "Targeted phototherapy." https://www.uptodate.com/contents/targeted-phototherapy (accessed 11/6/22, 2022).

[10] J. I. Silverberg, A. M. Tallman, W. C. Ports, R. A. Gerber, H. Tan, and M. A. Zielinski, "Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area," (in eng), Acta Derm Venereol, vol. 100, no. 13, p. adv00170, Jun 11 2020, doi: 10.2340/00015555-3489.

[11] J. Rajkumar, N. Jetter, K. Samuels, and A. Schwartz, "Combined antibiotic, steroid, and moisturizer for atopic dermatitis: A two-year case series of patient-reported outcomes," (in eng), Pediatr Dermatol, vol. 38, no. 3, pp. 623-628, May 2021, doi: 10.1111/pde.14458.

[12] S. H. Yu, A. M. Drucker, M. Lebwohl, and J. I. Silverberg, "A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis," (in eng), J Am Acad Dermatol, vol. 78, no. 4, pp. 733-740.e11, Apr 2018, doi: 10.1016/j.jaad.2017.09.074.

[13] L. H. Broersen, A. M. Pereira, J. O. Jørgensen, and O. M. Dekkers, "Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis," (in eng), J Clin Endocrinol Metab, vol. 100, no. 6, pp. 2171-80, Jun 2015, doi: 10.1210/jc.2015-1218.

[14] S. S. Lee, A. W. Tan, and Y. C. Giam, "Cyclosporin in the treatment of severe atopic dermatitis: a retrospective study," (in eng), Ann Acad Med Singap, vol. 33, no. 3, pp. 311-3, May 2004.

[15] S. Haw, M. K. Shin, and C. R. Haw, "The Efficacy and Safety of Long-term Oral Cyclosporine Treatment for Patients with Atopic Dermatitis," (in eng), Ann Dermatol, vol. 22, no. 1, pp. 9-15, Feb 2010, doi: 10.5021/ad.2010.22.1.9.

[16] J. Spergel and P. Lio. "Management of severe atopic dermatitis (eczema) in children." https://www.uptodate.com/contents/management-of-severe-atopic-dermatitis-eczema-in-children (accessed 11/6/22, 2022).

[17] N. R. Fuggle, W. Bragoli, A. Mahto, M. Glover, A. E. Martinez, and V. A. Kinsler, "The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring," (in eng), J Am Acad Dermatol, vol. 72, no. 1, pp. 108-14, Jan 2015, doi: 10.1016/j.jaad.2014.08.048.

[18] D. Siegels et al., "Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis," (in eng), Allergy, vol. 76, no. 4, pp. 1053-1076, Apr 2021, doi: 10.1111/all.14631.

[19] K. Phan and S. D. Smith, "Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis," (in eng), J Dermatolog Treat, vol. 31, no. 8, pp. 810-814, Dec 2020, doi: 10.1080/09546634.2019.1642996.

[20] L. Bakaa et al., "Bleach baths for atopic dermatitis: A systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE," (in eng), Ann Allergy Asthma Immunol, vol. 128, no. 6, pp. 660-668.e9, Jun 2022, doi: 10.1016/j.anai.2022.03.024.

[21] A. C. Devillers and A. P. Oranje, "Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature," (in eng), Br J Dermatol, vol. 154, no. 4, pp. 579-85, Apr 2006, doi: 10.1111/j.1365-2133.2006.07157.x.

[22] K. Papp et al., "Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies," (in eng), J Am Acad Dermatol, vol. 85, no. 4, pp. 863-872, Oct 2021, doi: 10.1016/j.jaad.2021.04.085.

[23] A. Blauvelt et al., "Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial," (in eng), JAMA Dermatol, vol. 157, no. 9, pp. 1047-1055, Sep 1 2021, doi: 10.1001/jamader

[24] H. Saeki, K. Ito, D. Yokota, and H. Tsubouchi, "Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial," (in eng), J Am Acad Dermatol, vol. 86, no. 3, pp. 607-614, Mar 2022, doi: 10.1016/j.jaad.2021.10.027.

[25] A. S. Paller, L. Stein Gold, J. Soung, A. M. Tallman, D. S. Rubenstein, and M. Gooderham, "Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis," (in eng), J Am Acad Dermatol, vol. 84, no. 3, pp. 632-638, Mar 2021, doi: 10.1016/j.jaad.2020.05.135.

[26] J. Peppers et al., "A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis," (in eng), J Am Acad Dermatol, vol. 80, no. 1, pp. 89-98.e3, Jan 2019, doi: 10.1016/j.jaad.2018.06.047.

[27] "Revolutionizing Atopic Dermatitis, 13–14 December 2020," British Journal of Dermatology, https://doi.org/10.1111/bjd.19722 vol. 184, no. 3, pp. e56-e87, 2021/03/01 2021, doi: https://doi.org/10.1111/bjd.19722.

[28] A. Blauvelt et al., "Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3," (in eng), Dermatol Ther (Heidelb), vol. 12, no. 11, pp. 2499-2516, Nov 2022, doi: 10.1007/s13555-022-00805-y.

[29] E. Guttman-Yassky et al., "Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial," (in eng), JAMA Dermatol, vol. 156, no. 4, pp. 411-420, Apr 1 2020, doi: 10.1001/jamadermatol.2020.0079.

[30] J. I. Silverberg et al., "Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus," (in eng), J Allergy Clin Immunol, vol. 145, no. 1, pp. 173-182, Jan 2020, doi: 10.1016/j.jaci.2019.08.013.

[31] S. Chan, V. Cornelius, S. Cro, J. I. Harper, and G. Lack, "Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial," (in eng), JAMA Pediatr, vol. 174, no. 1, pp. 29-37, Jan 1 2020, doi: 10.1001/jamapediatrics.2019.4476.

[32] E. L. Simpson et al., "Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)," (in eng), J Am Acad Dermatol, vol. 85, no. 1, pp. 62-70, Jul 2021, doi: 10.1016/j.jaad.2021.02.028.

[33] E. L. Simpson et al., "Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial," (in eng), Lancet, vol. 396, no. 10246, pp. 255-266, Jul 25 2020, doi: 10.1016/s0140-6736(20)30732-7.

[33] E. L. Simpson et al., "Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial," (in eng), Lancet, vol. 396, no. 10246, pp. 255-266, Jul 25 2020, doi: 10.1016/s0140-6736(20)30732-7.

[34] Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). JAMA Dermatol. 2023;159(2):182–191. doi:10.1001/jamadermatol.2022.5534

[35] Rahman MF, Nandi AK, Kabir S, Kamal M, Basher MS, Banu LA. Topical Tacrolimus versus Hydrocortisone on Atopic Dermatitis in Paediatric Patients: A Randomized Controlled Trial. Mymensingh Med J. 2015 Jul;24(3):457-63. PMID: 26329939.

[36] Yang DY, Li L, Lu T, Jing WW, Liu X, Li XL. Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study. Arch Dermatol Res. 2022 Aug 21. doi: 10.1007/s00403-022-02380-w. Epub ahead of print. PMID: 35989340.

[37] E. Guttman. “New Treatment for Moderate to Severe Atopic Dermatitis Shows Promising Long-Term Results” https://www.mountsinai.org/about/newsroom/2022/new-treatment-for-moderate-to-severe-atopic-dermatitis-shows-promising-long-term-results

[38] Lé AM, Torres T. OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics. 2022 Dec 8;14(12):2753. doi: 10.3390/pharmaceutics14122753. PMID: 36559247; PMCID: PMC9787630.